Anzeige
Mehr »
Freitag, 07.08.2026 - Börsentäglich über 12.000 News
Schwere Seltene Erden: Entsteht hier die nächste Milliardenstory?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LC2W | ISIN: US29089Q1058 | Ticker-Symbol: ER4
Tradegate
07.08.26 | 13:35
4,664 Euro
+1,57 % +0,072
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
EMERGENT BIOSOLUTIONS INC Chart 1 Jahr
5-Tage-Chart
EMERGENT BIOSOLUTIONS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,6064,71813:49
4,6264,71813:46

Aktuelle News zur EMERGENT BIOSOLUTIONS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoEmergent Bio slips despite Q2 beat amid cost-cutting plan9
MiEmergent Biosolutions Non-GAAP EPS of $0.60 beats by $0.49, revenue of $234.3M beats by $56.8M5
MiEmergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment4
EMERGENT BIOSOLUTIONS Aktie jetzt für 0€ handeln
MiEmergent BioSolutions Reports Second Quarter 2026 Financial Results88Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior yearSecond Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3...
► Artikel lesen
MiEmergent BioSolutions Inc. - 8-K, Current Report2
22.07.Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 202616
29.06.Emergent BioSolutions Secures $52.7 Million U.S. Government Contract Modification For ACAM20009
29.06.Emergent BioSolutions Inc. - 8-K, Current Report2
29.06.Emergent BioSolutions wins $52.7m smallpox vaccine contract2
29.06.Emergent BioSolutions erhält Auftrag über 52,7 Mio. US-Dollar für Pockenimpfstoff3
29.06.Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government2
04.06.Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdose4
28.05.Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Support U.S. Biodefense Strategy249GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the...
► Artikel lesen
20.05.Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization3
01.05.Emergent BioSolutions Q1 2026 slides: revenue tops guidance amid turnaround15
01.05.Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript2
30.04.Emergent BioSolutions Reports First Quarter 2026 Financial Results318First Quarter 2026 Total Revenues of $156.1 millionFirst Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4%First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA...
► Artikel lesen
30.04.Emergent BioSolutions Inc. - S-8, Securities to be offered to employees in employee benefit plans-
30.04.Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox4
30.04.Emergent BioSolutions Inc. - 8-K, Current Report2
Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1